Viral Hemorrhagic Fever Treatment Market

Global Viral Hemorrhagic Fever Treatment Market by Type (Ebola, Yellow Fever, Rift Valley Fever, Marburg, Lassa Fever, Lymphocytic Choriomeningitis, Hantavirus Pulmonary Syndrome (HPS), and Others), By Medications (Medications [Rebetol, Virazole, and Others], Surgery, and Others) By End-User (Hospitals/Clinics, Pharmaceuticals, Research Institutes, and Others), and Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa)

  • Report ID: HC-3851
  • Author: Growth Market Reports
  • Rating: 4.9
  • Total Reviews: 2
  • No. Of Pages: 247
  • Format:
  • Pub. Date: 12-01-2022
  • Share:

Market Outlook:

The global viral hemorrhagic fever treatment market was valued at USD 1,303.2 million in 2020 and is projected to reach USD 1,889.7 million by 2028, expanding at a CAGR of 4.9% during the forecast period. Viral hemorrhagic fever (VHF) is an infectious disease that infects humans and animals. These severe, life-threatening infections cause fever, damage to the walls of blood vessels, and obstruct the clotting of blood, making them leak. The VHF virus festers in endemic areas where its host species live. VHF include yellow fever, Ebola, dengue, Marburg, Lassa, South American VHF, Crimean-Congo, and Hantaan that have recently appeared in various parts of the world. Research activities for product development in laboratories were impeded due to the COVID-19 outbreak. This, in turn, hinders the market. Recurrent dengue epidemic in tropical countries and the SARS‐CoV‐2 pandemic are worldwide health threats. Virus‐caused infections show minor symptoms; however, they cause severe infections. Growing research to develop a VHF medical kit to detect diseases is expected to drive the market.

Viral Hemorrhagic Fever Treatment Market Key Takeaways

Attributes

Details

Report Title

Viral Hemorrhagic Fever Treatment Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Type (Ebola, Yellow Fever, Rift Valley Fever, Marburg, Lassa Fever, Lymphocytic Choriomeningitis, Hantavirus Pulmonary Syndrome (HPS), and Others), Medications (Medications [Rebetol, Virazole, and Others], Surgery, and Others) End-User (Hospitals/Clinics, Pharmaceuticals, Research Institutes, and Others)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered

Sanofi-aventis U.S. LLC, Taj Pharmaceuticals Limited, Bavarian Nordic, Merck Sharp & Dohme Corp., AdvaCare Pharma, Aprazer., Flagship Biotech International Private Limited., Biosynth Carbosynth., SAINTROY LIFESCIENCE, Nvron Life Science Limited, Bausch Health Companies Inc., and MBA Pharmaceuticals Pvt Ltd.

Market Dynamics

Rising prevalence of VHF across the globe

VHF are a group of illnesses that affect multiple organs in the body. VHF is caused by several families of viruses including Arenaviridae (Lassa fever and new world hemorrhagic fever), Filoviridae (Ebola and Marburg viruses), Flaviviridae (yellow fever, Omsk hemorrhagic fever, and dengue), and Bunyaviridae (Rift Valley fever and Crimean-Congo fever).(5) The most prevalent VHF in the Eastern Mediterranean Area is yellow fever, dengue, Crimean–Congo hemorrhagic fever, and Ebola hemorrhagic fever. (6) According to WHO, the average Marburg viruses (MVD) case death rate is about 50%, Marburg viruses (MVD) Case death rates varied from 24% to 88% in the past outbreaks reliant on virus strain and case management. The emergence and recurrence of VHF is a growing burden worldwide which is expected to propel the growth of the VHF treatment market across the globe.

Lack of hygiene among people

Growing unhygienic lifestyle among the population is expected to rise various illnesses, disabilities, and even death. In recent periods, lifestyle is a significant factor in health. According to WHO, around 60% of illnesses are related to the leading poor quality of life, and millions of people lead an unhealthy lifestyle. In 2019, the number of people elderly aged 60 years and above was 1 billion, this number is expected to increase to 1.4 billion by 2030 and nearly 2.1 billion by 2050, and about 80% of elder people are living in low- and middle-income countries, reported by WHO. (9) The rising geriatric population, increasing prevalence of VHF in the coming decades, particularly in emerging countries is anticipated to fuel the VHF treatment market.

Restraints

Adverse effects and low awareness regarding the treatment in developing countries

The risk of severe adverse events following immunization (AEFI) is high in people aged over 60 years and with serious immunodeficiency people due to symptomatic HIV/AIDS. Lack of awareness regarding VHF in some developing nations, such as those in Asia Pacific and the Middle East & Africa due to lack of interactivity within the people, poor diagnosis, lack of trained clinical staff, and low vector control. These factors hamper the VHF treatment market growth during the forecast period.

High cost of treatment and less efficacy of drug treatment

Excessive Viral Hemorrhagic Fever Treatment and/or caffeine consumption causes side effects such as insomnia, restlessness, nervousness, stomach upset, vomiting, nausea, and increases breathing and heart rate. Rising awareness regarding these effects is likely to hamper the Viral Hemorrhagic Fever Treatment market. There is growing concern about prospective adverse effects of caffeine in children on repeated use.

Opportunity

Government initiatives toward VHF

Governments have taken initiatives to develop and manufacture advanced products for the treatment and diagnosis of VHF, which is creating lucrative opportunities in the market. The Ebola virus disease outbreak occurrence in 2013-2016, the US government selected certain healthcare associations as Ebola treatment centers (ETCs) to better prepare for future emerging infectious disease outbreaks. In 2017, WHO has launched the Eliminate Yellow fever Epidemics (EYE) Strategy for yellow fever is an unprecedented initiative. According to WHO, the program fundings the US and other countries in developing national prevention strategies and improving laboratory diagnostics for Lassa fever and other dangerous diseases. Increasing global travel without restriction in some countries, rising government fundings in R&D activities, and decreasing healthcare expenditure are fueling the expansion of the VHF treatment market in the future.

Segmental Outlook

The global Viral Hemorrhagic Fever Treatment market is segmented on the basis of types, treatment types, end-users, and regions.

Based on type, the global viral hemorrhagic fever treatment market is segmented into Ebola, Yellow Fever, Rift Valley Fever, Marburg, Lassa Fever, Lymphocytic Choriomeningitis, Hantavirus Pulmonary Syndrome (HPS), and others. The others segment is further segmented into Crimean-Congo hemorrhagic fever (CCHF), Omsk hemorrhagic fever virus, Kyasanur Forest Disease (KFD) virus, SARS, Nipah virus encephalitis, and Pandemic influenza. The Ebola segment held a significant market share and is anticipated to grow in the coming years. Ebola is an infectious disease formerly known as Ebola hemorrhagic fever, which is a rare & severe infection in humans. Supportive care and vaccines available in the market include Ervebo vaccine, which is effective against the species Zaire ebolavirus.

Viral Hemorrhagic Fever Treatment Market By Type

Based on treatment type, the global viral hemorrhagic fever treatment market is segmented into medications (Rebetol, Virazole, and others (immune-modulating drugs, monoclonal antibodies)), surgery, and others. The others segment is fragmented into supportive care hospital therapy, vaccines. The medications segment held a significant share of the market. The others segment includes immune-modulating drugs and monoclonal antibodies for VHF treatment. Presently, there is no particular treatment existing for viral hemorrhagic fevers illness. Some antiviral drugs are effective against VHF such as ribavirin (Rebetol, Virazole) is reducing and prevents infections.

Viral Hemorrhagic Fever Treatment Market By Treatment Type

Based on end-users, the global viral hemorrhagic fever treatment market is segmented into hospitals/clinics, biotech & pharmaceutical industry, research institutes, and others. The other segment is sub-segmented into homecare settings and Ambulatory care settings. The hospitals/clinics segment held a significant share of the market. Hospitals are major providers of VHF treatment, owing to the outbreak of rising hospitalization of VHF patients, growing government initiatives towards the healthcare infrastructure, and advancement in disease diagnosis technology.

Regional Outlook

Based on regions, the global viral hemorrhagic fever treatment is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America held a significant market share, due to it has well-established R&D laboratory, increasing prevalence of VHF illness, and adoption of cutting-edge healthcare facilities. VHF commonly occurs in tropical or humid areas. The people in the US contract the disease by traveling to the tropical areas, which is expected to fuel the market in the US. The viral hemorrhagic fever treatment market in Europe is growing, due to increasing demand for the treatment of such as Lassa fever, dengue hemorrhagic fever, yellow fever, and Marburg fever, growing awareness among people, and high prevalence of VHF in these regions. Europe is a center of medical devices and the diagnosis of VHF illness, which is creating lucrative opportunities in the market.

Viral Hemorrhagic Fever Treatment Market By Regions

 Key Benefits for Industry Participants & Stakeholders

  • In-depth Analysis of the Global Viral Hemorrhagic Fever Treatment market
  • Historical, Current and Projected Market Size in terms of Value and Volume
  • Potential & Niche Segments and Regions Exhibiting Promising Growth Covered
  • Industry Drivers, Restraints and Opportunities Covered in the Study
  • Recent Industry Trends and Developments
  • Competitive Landscape & Strategies of Key Players
  • Neutral Perspective on Global Viral Hemorrhagic Fever Treatment Market Performance

Segments

Key Segments Covered
By Types
  • Ebola
  • Yellow Fever
  • Rift Valley Fever
  • Marburg
  • Lassa Fever
  • Lymphocytic Choriomeningitis
  • Hantavirus Pulmonary Syndrome (HPS)
  • Others
By Treatment Type
  • Medications    
    • Rebetol
    • Virazole
    • Others
  • Surgery             
  • Others
By End-User
  • Hospitals/Clinics
  • Pharmaceuticals
  • Research Institutes     
  • Others
By Regions
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Key Market Players Profiled in the Report
  • Sanofi-aventis U.S. LLC
  • Taj Pharmaceuticals Limited
  • Bavarian Nordic
  • Merck Sharp & Dohme Corp.
  • AdvaCare Pharma
  • Aprazer.
  • Flagship Biotech International Private Limited.
  • Biosynth Carbosynth.
  • SAINTROY LIFESCIENCE
  • Nvron Life Science Limited
  • Bausch Health Companies Inc.
  • MBA Pharmaceuticals Pvt Ltd

Competitive Landscape

  • Top players in the market include Merck Sharp & Dohme Corp., Sanofi-Aventis U.S. LLC, Bavarian Nordic, Hawaii Biotech Inc. and Taj Pharmaceuticals Limited These companies are considered as key manufacturers of piezoelectric element based on their revenue, product offerings, regional presence, and supply chain management system.
  • The players are adopting key strategies such as acquisition, collaborations, and geographical expansion where potential opportunity for the Viral Hemorrhagic Fever Treatment market.

Viral Hemorrhagic Fever Treatment Market By Key Players

  •  
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Viral Hemorrhagic Fever Treatment Market Overview
   4.1 Introduction
      4.1.1 Market Taxonomy
      4.1.2 Market Definition
      4.1.3 Macro-Economic Factors Impacting the Market Growth
   4.2 Viral Hemorrhagic Fever Treatment Market Dynamics
      4.2.1 Market Drivers
      4.2.2 Market Restraints
      4.2.3 Market Opportunity
   4.3 Viral Hemorrhagic Fever Treatment Market - Supply Chain Analysis
      4.3.1 List of Key Suppliers
      4.3.2 List of Key Distributors
      4.3.3 List of Key Consumers
   4.4 Key Forces Shaping the Viral Hemorrhagic Fever Treatment Market
      4.4.1 Bargaining Power of Suppliers
      4.4.2 Bargaining Power of Buyers
      4.4.3 Threat of Substitution
      4.4.4 Threat of New Entrants
      4.4.5 Competitive Rivalry
   4.5 Global Viral Hemorrhagic Fever Treatment Market Size & Forecast, 2018-2028
      4.5.1 Viral Hemorrhagic Fever Treatment Market Size and Y-o-Y Growth
      4.5.2 Viral Hemorrhagic Fever Treatment Market Absolute $ Opportunity
   4.6 Regulation Overview
Chapter 5 Global Viral Hemorrhagic Fever Treatment Market Analysis and Forecast By Types
   5.1 Introduction
      5.1.1 Key Market Trends & Growth Opportunities By Types
      5.1.2 Basis Point Share (BPS) Analysis By Types
      5.1.3 Absolute $ Opportunity Assessment By Types
   5.2 Viral Hemorrhagic Fever Treatment Market Size Forecast By Types
      5.2.1 Ebola
      5.2.2 Yellow Fever
      5.2.3 Rift Valley Fever
      5.2.4 Marburg
      5.2.5 Lassa Fever
      5.2.6 Lymphocytic Choriomeningitis
      5.2.7 Hantavirus Pulmonary Syndrome (HPS)
      5.2.8 Others
   5.3 Market Attractiveness Analysis By Types
Chapter 6 Global Viral Hemorrhagic Fever Treatment Market Analysis and Forecast By Treatment Type
   6.1 Introduction
      6.1.1 Key Market Trends & Growth Opportunities By Treatment Type
      6.1.2 Basis Point Share (BPS) Analysis By Treatment Type
      6.1.3 Absolute $ Opportunity Assessment By Treatment Type
   6.2 Viral Hemorrhagic Fever Treatment Market Size Forecast By Treatment Type
      6.2.1 Medications
         6.2.1.1 Rebetol
         6.2.1.2 Virazole
         6.2.1.3 Others
      6.2.2 Surgery
      6.2.3 Others
   6.3 Market Attractiveness Analysis By Treatment Type
Chapter 7 Global Viral Hemorrhagic Fever Treatment Market Analysis and Forecast By End-User
   7.1 Introduction
      7.1.1 Key Market Trends & Growth Opportunities By End-User
      7.1.2 Basis Point Share (BPS) Analysis By End-User
      7.1.3 Absolute $ Opportunity Assessment By End-User
   7.2 Viral Hemorrhagic Fever Treatment Market Size Forecast By End-User
      7.2.1 Hospitals/Clinics
      7.2.2 Pharmaceuticals
      7.2.3 Research Institutes
      7.2.4 Others   
   7.3 Market Attractiveness Analysis By End-User
Chapter 8 Global Viral Hemorrhagic Fever Treatment Market Analysis and Forecast by Region
   8.1 Introduction
      8.1.1 Key Market Trends & Growth Opportunities by Region
      8.1.2 Basis Point Share (BPS) Analysis by Region
      8.1.3 Absolute $ Opportunity Assessment by Region
   8.2 Viral Hemorrhagic Fever Treatment Market Size Forecast by Region
      8.2.1 North America
      8.2.2 Europe
      8.2.3 Asia Pacific
      8.2.4 Latin America
      8.2.5 Middle East & Africa (MEA)
   8.3 Market Attractiveness Analysis by Region
Chapter 9 Coronavirus Disease (COVID-19) Impact
   9.1 Introduction
   9.2 Current & Future Impact Analysis
   9.3 Economic Impact Analysis
   9.4 Government Policies
   9.5 Investment Scenario
Chapter 10 North America Viral Hemorrhagic Fever Treatment Analysis and Forecast
   10.1 Introduction
   10.2 North America Viral Hemorrhagic Fever Treatment Market Size Forecast by Country
      10.2.1 U.S.
      10.2.2 Canada
   10.3 Basis Point Share (BPS) Analysis by Country
   10.4 Absolute $ Opportunity Assessment by Country
   10.5 Market Attractiveness Analysis by Country
   10.6 North America Viral Hemorrhagic Fever Treatment Market Size Forecast By Types
      10.6.1 Ebola
      10.6.2 Yellow Fever
      10.6.3 Rift Valley Fever
      10.6.4 Marburg
      10.6.5 Lassa Fever
      10.6.6 Lymphocytic Choriomeningitis
      10.6.7 Hantavirus Pulmonary Syndrome (HPS)
      10.6.8 Others
   10.7 Basis Point Share (BPS) Analysis By Types
   10.8 Absolute $ Opportunity Assessment By Types
   10.9 Market Attractiveness Analysis By Types
   10.10 North America Viral Hemorrhagic Fever Treatment Market Size Forecast By Treatment Type
      10.10.1 Medications
         10.10.1.1 Rebetol
         10.10.1.2 Virazole
         10.10.1.3 Others
      10.10.2 Surgery
      10.10.3 Others
   10.11 Basis Point Share (BPS) Analysis By Treatment Type
   10.12 Absolute $ Opportunity Assessment By Treatment Type
   10.13 Market Attractiveness Analysis By Treatment Type
   10.14 North America Viral Hemorrhagic Fever Treatment Market Size Forecast By End-User
      10.14.1 Hospitals/Clinics
      10.14.2 Pharmaceuticals
      10.14.3 Research Institutes
      10.14.4 Others
   10.15 Basis Point Share (BPS) Analysis By End-User
   10.16 Absolute $ Opportunity Assessment By End-User
   10.17 Market Attractiveness Analysis By End-User
Chapter 11 Europe Viral Hemorrhagic Fever Treatment Analysis and Forecast
   11.1 Introduction
   11.2 Europe Viral Hemorrhagic Fever Treatment Market Size Forecast by Country
      11.2.1 Germany
      11.2.2 France
      11.2.3 Italy
      11.2.4 U.K.
      11.2.5 Spain
      11.2.6 Russia
      11.2.7 Rest of Europe
   11.3 Basis Point Share (BPS) Analysis by Country
   11.4 Absolute $ Opportunity Assessment by Country
   11.5 Market Attractiveness Analysis by Country
   11.6 Europe Viral Hemorrhagic Fever Treatment Market Size Forecast By Types
      11.6.1 Ebola
      11.6.2 Yellow Fever
      11.6.3 Rift Valley Fever
      11.6.4 Marburg
      11.6.5 Lassa Fever
      11.6.6 Lymphocytic Choriomeningitis
      11.6.7 Hantavirus Pulmonary Syndrome (HPS)
      11.6.8 Others
   11.7 Basis Point Share (BPS) Analysis By Types
   11.8 Absolute $ Opportunity Assessment By Types
   11.9 Market Attractiveness Analysis By Types
   11.10 Europe Viral Hemorrhagic Fever Treatment Market Size Forecast By Treatment Type
      11.10.1 Medications
         11.10.1.1 Rebetol
         11.10.1.2 Virazole
         11.10.1.3 Others
      11.10.2 Surgery
      11.10.3 Others
   11.11 Basis Point Share (BPS) Analysis By Treatment Type
   11.12 Absolute $ Opportunity Assessment By Treatment Type
   11.13 Market Attractiveness Analysis By Treatment Type
   11.14 Europe Viral Hemorrhagic Fever Treatment Market Size Forecast By End-User
      11.14.1 Hospitals/Clinics
      11.14.2 Pharmaceuticals
      11.14.3 Research Institutes
      11.14.4 Others
   11.15 Basis Point Share (BPS) Analysis By End-User
   11.16 Absolute $ Opportunity Assessment By End-User
   11.17 Market Attractiveness Analysis By End-User
Chapter 12 Asia Pacific Viral Hemorrhagic Fever Treatment Analysis and Forecast
   12.1 Introduction
   12.2 Asia Pacific Viral Hemorrhagic Fever Treatment Market Size Forecast by Country
      12.2.1 China
      12.2.2 Japan
      12.2.3 South Korea
      12.2.4 India
      12.2.5 Australia
      12.2.6 South East Asia (SEA)
      12.2.7 Rest of Asia Pacific (APAC)
   12.3 Basis Point Share (BPS) Analysis by Country
   12.4 Absolute $ Opportunity Assessment by Country
   12.5 Market Attractiveness Analysis by Country
   12.6 Asia Pacific Viral Hemorrhagic Fever Treatment Market Size Forecast By Types
      12.6.1 Ebola
      12.6.2 Yellow Fever
      12.6.3 Rift Valley Fever
      12.6.4 Marburg
      12.6.5 Lassa Fever
      12.6.6 Lymphocytic Choriomeningitis
      12.6.7 Hantavirus Pulmonary Syndrome (HPS)
      12.6.8 Others
   12.7 Basis Point Share (BPS) Analysis By Types
   12.8 Absolute $ Opportunity Assessment By Types
   12.9 Market Attractiveness Analysis By Types
   12.10 Asia Pacific Viral Hemorrhagic Fever Treatment Market Size Forecast By Treatment Type
      12.10.1 Medications
         12.10.1.1 Rebetol
         12.10.1.2 Virazole
         12.10.1.3 Others
      12.10.2 Surgery
      12.10.3 Others
   12.11 Basis Point Share (BPS) Analysis By Treatment Type
   12.12 Absolute $ Opportunity Assessment By Treatment Type
   12.13 Market Attractiveness Analysis By Treatment Type
   12.14 Asia Pacific Viral Hemorrhagic Fever Treatment Market Size Forecast By End-User
      12.14.1 Hospitals/Clinics
      12.14.2 Pharmaceuticals
      12.14.3 Research Institutes
      12.14.4 Others
   12.15 Basis Point Share (BPS) Analysis By End-User
   12.16 Absolute $ Opportunity Assessment By End-User
   12.17 Market Attractiveness Analysis By End-User
Chapter 13 Latin America Viral Hemorrhagic Fever Treatment Analysis and Forecast
   13.1 Introduction
   13.2 Latin America Viral Hemorrhagic Fever Treatment Market Size Forecast by Country
      13.2.1 Brazil
      13.2.2 Mexico
      13.2.3 Rest of Latin America (LATAM)
   13.3 Basis Point Share (BPS) Analysis by Country
   13.4 Absolute $ Opportunity Assessment by Country
   13.5 Market Attractiveness Analysis by Country
   13.6 Latin America Viral Hemorrhagic Fever Treatment Market Size Forecast By Types
      13.6.1 Ebola
      13.6.2 Yellow Fever
      13.6.3 Rift Valley Fever
      13.6.4 Marburg
      13.6.5 Lassa Fever
      13.6.6 Lymphocytic Choriomeningitis
      13.6.7 Hantavirus Pulmonary Syndrome (HPS)
      13.6.8 Others
   13.7 Basis Point Share (BPS) Analysis By Types
   13.8 Absolute $ Opportunity Assessment By Types
   13.9 Market Attractiveness Analysis By Types
   13.10 Latin America Viral Hemorrhagic Fever Treatment Market Size Forecast By Treatment Type
      13.10.1 Medications
         13.10.1.1 Rebetol
         13.10.1.2 Virazole
         13.10.1.3 Others
      13.10.2 Surgery
      13.10.3 Others
   13.11 Basis Point Share (BPS) Analysis By Treatment Type
   13.12 Absolute $ Opportunity Assessment By Treatment Type
   13.13 Market Attractiveness Analysis By Treatment Type
   13.14 Latin America Viral Hemorrhagic Fever Treatment Market Size Forecast By End-User
      13.14.1 Hospitals/Clinics
      13.14.2 Pharmaceuticals
      13.14.3 Research Institutes
      13.14.4 Others
   13.15 Basis Point Share (BPS) Analysis By End-User
   13.16 Absolute $ Opportunity Assessment By End-User
   13.17 Market Attractiveness Analysis By End-User
Chapter 14 Middle East & Africa (MEA) Viral Hemorrhagic Fever Treatment Analysis and Forecast
   14.1 Introduction
   14.2 Middle East & Africa (MEA) Viral Hemorrhagic Fever Treatment Market Size Forecast by Country
      14.2.1 Saudi Arabia
      14.2.2 South Africa
      14.2.3 UAE
      14.2.4 Rest of Middle East & Africa (MEA)
   14.3 Basis Point Share (BPS) Analysis by Country
   14.4 Absolute $ Opportunity Assessment by Country
   14.5 Market Attractiveness Analysis by Country
   14.6 Middle East & Africa (MEA) Viral Hemorrhagic Fever Treatment Market Size Forecast By Types
      14.6.1 Ebola
      14.6.2 Yellow Fever
      14.6.3 Rift Valley Fever
      14.6.4 Marburg
      14.6.5 Lassa Fever
      14.6.6 Lymphocytic Choriomeningitis
      14.6.7 Hantavirus Pulmonary Syndrome (HPS)
      14.6.8 Others
   14.7 Basis Point Share (BPS) Analysis By Types
   14.8 Absolute $ Opportunity Assessment By Types
   14.9 Market Attractiveness Analysis By Types
   14.10 Middle East & Africa (MEA) Viral Hemorrhagic Fever Treatment Market Size Forecast By Treatment Type
      14.10.1 Medications
         14.10.1.1 Rebetol
         14.10.1.2 Virazole
         14.10.1.3 Others
      14.10.2 Surgery
      14.10.3 Others
   14.11 Basis Point Share (BPS) Analysis By Treatment Type
   14.12 Absolute $ Opportunity Assessment By Treatment Type
   14.13 Market Attractiveness Analysis By Treatment Type
   14.14 Middle East & Africa (MEA) Viral Hemorrhagic Fever Treatment Market Size Forecast By End-User
      14.14.1 Hospitals/Clinics
      14.14.2 Pharmaceuticals
      14.14.3 Research Institutes
      14.14.4 Others
   14.15 Basis Point Share (BPS) Analysis By End-User
   14.16 Absolute $ Opportunity Assessment By End-User
   14.17 Market Attractiveness Analysis By End-User
Chapter 15 Competition Landscape
   15.1 Viral Hemorrhagic Fever Treatment Market: Competitive Dashboard
   15.2 Global Viral Hemorrhagic Fever Treatment Market: Market Share Analysis, 2020
   15.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
      15.3.1 Sanofi-aventis U.S. LLC
      15.3.2 Taj Pharmaceuticals Limited
      15.3.3 Bavarian Nordic
      15.3.4 Merck Sharp & Dohme Corp.
      15.3.5 AdvaCare Pharma
      15.3.6 Aprazer.
      15.3.7 Flagship Biotech International Private Limited.
      15.3.8 Biosynth Carbosynth.
      15.3.9 SAINTROY LIFESCIENCE
      15.3.10 Nvron Life Science Limited
      15.3.11 Bausch Health Companies Inc.
      15.3.12 MBA Pharmaceuticals Pvt Ltd
 
Key Segments Covered
By Types
  • Ebola
  • Yellow Fever
  • Rift Valley Fever
  • Marburg
  • Lassa Fever
  • Lymphocytic Choriomeningitis
  • Hantavirus Pulmonary Syndrome (HPS)
  • Others
By Treatment Type
  • Medications    
    • Rebetol
    • Virazole
    • Others
  • Surgery             
  • Others
By End-User
  • Hospitals/Clinics
  • Pharmaceuticals
  • Research Institutes     
  • Others
By Regions
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Key Market Players Profiled in the Report
  • Sanofi-aventis U.S. LLC
  • Taj Pharmaceuticals Limited
  • Bavarian Nordic
  • Merck Sharp & Dohme Corp.
  • AdvaCare Pharma
  • Aprazer.
  • Flagship Biotech International Private Limited.
  • Biosynth Carbosynth.
  • SAINTROY LIFESCIENCE
  • Nvron Life Science Limited
  • Bausch Health Companies Inc.
  • MBA Pharmaceuticals Pvt Ltd
  • Top players in the market include Merck Sharp & Dohme Corp., Sanofi-Aventis U.S. LLC, Bavarian Nordic, Hawaii Biotech Inc. and Taj Pharmaceuticals Limited These companies are considered as key manufacturers of piezoelectric element based on their revenue, product offerings, regional presence, and supply chain management system.
  • The players are adopting key strategies such as acquisition, collaborations, and geographical expansion where potential opportunity for the Viral Hemorrhagic Fever Treatment market.

Viral Hemorrhagic Fever Treatment Market By Key Players

  •  

Buy Report

FAQ Section

Some frequently asked quetions about this report!

Additional company profiles can be provided on request For a discussion related to above findings, click Speak to Analyst.

According to this Growth Market Reports report, the Viral Hemorrhagic Fever Treatment market is likely to register a CAGR of 4.9% during forecast period 2020-2027, with an anticipated valuation of USD 1,889.7 Mn by the end of the 2028.

In addition to market size (in US$ Million), Company Market Share (in % for base year 2019), and quality parameter overview is provided.

Factors such as competitive strength and market positioning are key areas considered while selecting top companies to be profiled.

Rising prevalence of VHF across the globe, Lack of hygiene among people, Increasing awareness about hemorrhagic fever, and Growing investments in R&D expected to act as a driving force for the market during forecast period.

The major applications of Viral Hemorrhagic Fever Treatment are Hospitals/Clinics, Biotech and Pharmaceutical Industry, Academic and research institutes, Patients, and Others.

The market is expected to witness a significant decrease in growth between 2019 and 2020 owing to the COVID 19 pandemic on the Viral Hemorrhagic Fever Treatment market.

The base year considered for the global Viral Hemorrhagic Fever Treatment market report is 2020. The complete analysis period is 2018 to 2028, wherein, 2018, and 2019 are the historic years, and the forecast is provided from 2021 to 2028.

Factors such as growth of government initiatives & regulations, healthcare industry, GDP, and economic impact expected to act as a driving force for the market.

Major Manufacturers Merck Sharp & Dohme Corp., Sanofi-Aventis U.S. LLC, Bavarian Nordic, Hawaii Biotech Inc. and Taj Pharmaceuticals Limited.